| Artificial Intelligence for Classification of Lung Nodules: A Review of Clinical Utility, Diagnostic Accuracy, Cost-Effectiveness, and Guidelines |
|
|
|
Health Technology Review |
Summary with Critical Appraisal |
Completed |
RC1228-000 |
| Clozapine Initiation for Schizophrenia: A Review of Clinical Effectiveness and Guidelines |
|
|
|
Health Technology Review |
Summary with Critical Appraisal |
Completed |
RC1229-000 |
| Pilocarpine for Radiotherapy-Induced Dry Mouth and Dry Eyes: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines |
|
|
|
Health Technology Review |
Summary with Critical Appraisal |
Completed |
RC1226-000 |
| Pharmacogenomic Testing in Depression: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines |
|
|
|
Health Technology Review |
Summary with Critical Appraisal |
Completed |
RC1232-000 |
| Major Depressive Disorder – Focused Critical Appraisal of a Network Meta-Analysis |
|
|
|
Health Technology Review |
Technology Review |
Completed |
HE0022-000 |
| Physical Activity for Chronic Osteoarthritic Knee Pain: A Review of Clinical Effectiveness |
|
|
|
Health Technology Review |
Summary with Critical Appraisal |
Completed |
RC1230-000 |
| Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer — Details |
|
|
|
Reimbursement Review |
|
Complete |
PC0183-000 |
| Entrectinib (TBD) for Neurotrophic Tyrosine Receptor Kinase (NTRK) Fusion-Positive Solid Tumours |
|
|
|
Reimbursement Review |
|
Withdrawn |
PC0157-000 |
| Atezolizumab (Tecentriq) for Advanced or Metastatic Triple-Negative Breast Cancer — Details |
|
|
|
Reimbursement Review |
|
Withdrawn |
PC0171-000 |
| Health Technology Update - Issue 26 |
|
|
|
Horizon Scan |
|
Completed |
EN0016-000 |
| CADTH Pharmaceutical Reviews Update — Issue 13 |
|
|
|
Reimbursement Review |
Pharmaceutical Review Update |
|
|
| Trastuzumab Emtansine (Kadcyla) for Early Breast Cancer (EBC) — Details |
|
|
|
Reimbursement Review |
|
Complete |
PC0182-000 |
| Cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma — Details |
|
|
|
Reimbursement Review |
|
Complete |
PC0187-000 |
| apomorphine hydrochloride |
|
|
|
Reimbursement Review |
|
Withdrawn |
SR0604-000 |
| Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy: A Critical Appraisal of the MENTOR Study |
|
|
|
Health Technology Review |
Technology Review |
Completed |
HA0001-000 |
| Utilization of Innovator Biologics and Biosimilars for Chronic Inflammatory Diseases in Canada: A Provincial Perspective |
|
|
|
Health Technology Review |
|
|
HO0007-HE0024 |
| Internet-Based Cognitive Behavioural Therapy for Post-Traumatic Stress Disorder |
|
|
|
Health Technology Review |
Optimal Use |
Completed |
OP0537-000 |
| Keytruda for Squamous NSCLC – Details |
|
|
|
Reimbursement Review |
|
Complete |
PC0176-000 |
| csDMARDS for Rheumatoid Arthritis |
|
|
|
Health Technology Review |
Technology Review |
Completed |
HE0029-000 |
| Magnetic Resonance-Guided Radiotherapy: MR-Simulation and MR-Linac |
|
|
|
Horizon Scan |
Emerging Health Technologies |
Completed |
EH0074-000 |
| Magnetic Resonance Guided Radiotherapy: MR-simulation, and MR-linac |
|
|
|
Horizon Scan |
|
Completed |
EH0074-000 |
| Elevated Vacuum Suspension Systems for Adults with Amputation: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines |
|
|
|
Health Technology Review |
Summary with Critical Appraisal |
Completed |
RC1224-000 |
| inotersen |
|
|
|
Reimbursement Review |
|
Complete |
SR0603-000 |
| Health Technology Update Issue 25 |
|
|
|
Horizon Scan |
|
|
EN0015-000 |
| lanadelumab |
|
|
|
Reimbursement Review |
|
Complete |
SR0618-000 |
